マルチプレックスアッセイ市場規模、シェア、動向、2031年までの世界予測

マルチプレックスアッセイ市場は、2026年には約71億5,000万米ドル規模と予測され、2031年には106億5,000万米ドルに達すると見込まれており、成長率は8.3%とに達するとMarketsandMarketsでは予測しています。

この着実な成長は、医療機関における早期診断、高精度バイオマーカー、および患者転帰の改善への注力の高まりによって牽引されている。疾患の複雑化、個別化医療の台頭、効率的でハイスループットな検査方法の必要性といった要因が、マルチプレックスアッセイに対する世界的な需要の高まりを後押ししています。

調査範囲：

本調査レポートは、マルチプレックスアッセイ市場を、製品・サービス（消耗品、機器、ソフトウェア・サービス）、タイプ（タンパク質マルチプレックスアッセイ、核酸マルチプレックスアッセイ、細胞ベースマルチプレックスアッセイ）、技術（フローサイトメトリー、蛍光検出、マルチプレックスリアルタイムPCR、発光、次世代シーケンシング（NGS）、その他の技術）、用途（研究開発、臨床診断）、エンドユーザー（製薬・バイオテクノロジー企業、病院・診断検査機関、学術・研究機関、受託研究機関、その他のエンドユーザー）、地域（北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ）別に分類しています。

本レポートでは、マルチプレックスアッセイ市場の成長に影響を与える主要な要因（推進要因、阻害要因、機会、課題など）に関する詳細な情報を提供しています。主要な業界プレーヤーの詳細な分析を実施し、事業概要、ソリューション、パートナーシップ、コラボレーション、事業拡大、契約、新製品発売、マルチプレックスアッセイ市場における最近の動向といった主要戦略に関する洞察を提供します。本レポートでは、マルチプレックスアッセイ市場のエコシステムにおける新興スタートアップ企業の競合分析も網羅しています。

本レポートを購入する理由：

本レポートは、マルチプレックスアッセイ市場全体およびそのサブセグメントの収益に関する最も正確な推定値を提供することで、市場リーダーおよび新規参入企業を支援します。また、関係者が競争環境を理解し、より深い洞察を得て、自社の事業をより適切に位置づけ、適切な市場参入戦略を策定するのに役立ちます。さらに、市場の動向を把握し、主要な推進要因、阻害要因、機会、課題に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します。

主要な推進要因（慢性疾患および感染症の発生率の上昇、シングルプレックスおよび従来型アッセイに対する利点、コンパニオン診断におけるマルチプレックスアッセイの使用の増加、早期疾患検出への注目の高まり、慢性疾患および感染症の発生率の上昇）、制約（マルチプレックスアッセイ機器に関連するコスト制約、規制上の課題および厳格な品質基準）、機会（分子およびタンパク質ベースの診断におけるバイオマーカーの検証の増加、分子およびタンパク質診断におけるバイオマーカー検証の進歩、新興市場への拡大）、および課題（熟練した専門家の不足、複雑なデータ分析および解釈）の分析。

• 製品開発／イノベーション：マルチプレックスアッセイ市場における今後の技術、研究開発活動、および新製品の発売に関する詳細な洞察。
• 市場開発：有望な市場に関する包括的な情報。本レポートは、様々な地域におけるマルチプレックスアッセイ市場を分析します。
• 市場の多様化：マルチプレックスアッセイ市場における新製品、未開拓地域、最近の動向、および投資に関する包括的な情報。
• 競合分析：サーモフィッシャーサイエンティフィック（米国）、イルミナ（米国）、バイオ・ラッド・ラボラトリーズ（米国）、ディアソリン（イタリア）、バイオメリュー（フランス）といった主要企業の市場シェア、成長戦略、製品ラインナップを詳細に分析します。

Report Description

The market for multiplex assays is projected to be valued at approximately USD 7.15 billion in 2026 and is expected to reach USD 10.65 billion by 2031, reflecting a 8.3% growth rate. This steady growth is driven by medical institutions’ growing focus on early diagnosis, accurate biomarkers, and improved patient outcomes. Factors such as the increasing complexity of diseases, the rise of personalized medicine, and the need for efficient, high-throughput testing methods are driving the growing global demand for multiplex assays.

“By product & service, the consumables segment is predicted to showcase the highest CAGR during the forecast period.”

The growth in this segment is primarily driven by the consistent need for multiplex assay kits, reagents, beads, primers, probes, and controls, all of which are essential for conducting analyses. The rising incidence of infectious diseases, cancers, and autoimmune conditions is expected to increase testing demand across various healthcare settings. This will boost demand for the segment in hospitals, diagnostic labs, and research facilities. Additionally, the expanding use of multiplex testing protocols and the development of new assays will further contribute to this growth.

“By technology, the Flow cytometry segment is projected to hold the largest share of the multiplex assay market in 2026.”

This market segment is dominant due to the widespread adoption of technology in hospitals and reference laboratories, enabling high-throughput and multiparametric testing with improved sensitivity, accuracy, and reproducibility in biomarker and cell analysis. Flow cytometry is among the most widely used instruments in immunology, oncology, and translational research, owing to its ability to rapidly analyze multiple markers in a single test. The demand for flow cytometers is primarily driven by the increasing number of diagnostic tests, scientific studies, and the need for disease profiling and therapy monitoring.

“The Asia Pacific is expected to register the fastest growth rate in the multiplex assay market.”

This region is experiencing rapid growth due to several factors, including the expansion of healthcare facilities and increased healthcare spending. The modernization of hospitals, laboratories, and diagnostic centers is also contributing to this growth. Additionally, the rising incidence of infectious diseases, cancer, and chronic conditions is driving the demand for advanced diagnostic tests. Furthermore, increased investments in biotechnology research, the expansion of pharmaceutical production facilities, and a growing number of diagnostic centers are fueling the growth of multiplex assays in the Asia Pacific region. Key countries contributing to this market growth include China, India, Japan, and South Korea, among others.

The break-up of the profile of primary participants in the multiplex assay market:

• By Company Type: Tier 1 (35%), Tier 2 (40%), and Tier 3 (15%)
• By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%)
• By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)

The key players in the multiplex assay market are Thermo Fisher Scientific, Inc. (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Danaher Corporation (US), Becton, Dickinson and Company (US), Merck KGaA (Germany), DiaSorin S.p.A. (Italy), Revvity, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies (US), Quanterix Corporation (US), and bioMérieux (France).

Research Coverage:

This research report categorizes the multiplex assay market by product & service (consumables, instruments, software & services), type (protein multiplex assays, nucleic acid multiplex assays, cell-based multiplex assays), technology (flow cytometry, fluorescence detection, multiplex real-time PCR, luminescence, next-generation sequencing (NGS), other technologies), application (research & development, clinical diagnostics), end user (pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, contract research organizations, other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the multiplex assay market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, key strategies, such as partnerships, collaborations, expansions, agreements, new product launches, and recent developments in the multiplex assay market. This report covers the competitive analysis of upcoming startups in the multiplex assay market ecosystem.

Reasons to buy this report:

The report will help market leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall multiplex assay market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (rising incidence of chronic and infectious diseases, advantages over singleplex and traditional assays, increasing use of multiplex assays in companion diagnostics, growing focus on early disease detection, rising incidence of chronic and infectious diseases), restraints (cost constraints associated with multiplex assay instrumentation, regulatory challenges and stringent quality standards), opportunities (growing validation of biomarkers in molecular and protein-based diagnostics, advancements in biomarker validation in molecular and protein diagnostics, expansion in emerging markets), and challenges (shortage of skilled professionals, complex data analysis and interpretation).
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the multiplex assay market.
• Market Development: Comprehensive information about lucrative markets; the report analyses the multiplex assay market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the multiplex assay market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Thermo Fisher Scientific, Inc. (US), Illumina, Inc (US), Bio-Rad Laboratories, Inc. (US), DiaSorin S.p.A. (Italy), and bioMérieux (France).

Table of Contents

1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.3 STUDY SCOPE 36
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 36
1.3.2 INCLUSIONS AND EXCLUSIONS 37
1.3.3 YEARS CONSIDERED 38
1.4 CURRENCY CONSIDERED 38
1.5 STAKEHOLDERS 38
1.6 SUMMARY OF CHANGES 39
2 EXECUTIVE SUMMARY 40
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 40
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 41
2.3 DISRUPTIVE TRENDS IN MULTIPLEX ASSAY MARKET 42
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 43
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 44
3 PREMIUM INSIGHTS 45
3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN MULTIPLEX ASSAY MARKET 45
3.2 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031 46
3.3 MULTIPLEX ASSAY MARKET, BY TYPE, 2026 VS. 2031 46
3.4 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2026 VS. 2031 47
3.5 MULTIPLEX ASSAY MARKET, BY APPLICATION, 2026 VS. 2031 47
3.6 MULTIPLEX ASSAY MARKET, BY END USER, 2026 VS. 2031 48
3.7 MULTIPLEX ASSAY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 48
4 MARKET OVERVIEW 49
4.1 INTRODUCTION 49
4.2 MARKET DYNAMICS 49
4.2.1 DRIVERS 50
4.2.1.1 Rising incidence of chronic and infectious diseases 50
4.2.1.2 Advantages over singleplex and traditional assays 52
4.2.1.3 Increasing use of multiplex assays in companion diagnostics 53
4.2.1.4 Growing focus on early disease detection 53
4.2.1.5 Expansion of biomarker-driven research 54
4.2.2 RESTRAINTS 55
4.2.2.1 Cost constraints associated with multiplex assay instrumentation 55
4.2.2.2 Regulatory challenges and stringent quality standards 55
4.2.3 OPPORTUNITIES 56
4.2.3.1 Growing validation of biomarkers in molecular and protein-based diagnostics 56
4.2.3.2 Expansion in emerging markets 56
4.2.4 CHALLENGES 57
4.2.4.1 Shortage of skilled professionals 57
4.2.4.2 Complex data analysis and interpretation 57
4.3 UNMET NEEDS AND WHITE SPACES 58
4.3.1 UNMET NEEDS IN MULTIPLEX ASSAY MARKET 58
4.3.2 WHITE SPACE OPPORTUNITIES 59
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 60
4.4.1 INTERCONNECTED MARKETS 60
4.4.2 CROSS-SECTOR OPPORTUNITIES 61
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 62
4.5.1 KEY MOVES AND STRATEGIC FOCUS 62
5 INDUSTRY TRENDS 63
5.1 PORTER’S FIVE FORCES ANALYSIS 63
5.1.1 BARGAINING POWER OF SUPPLIERS 64
5.1.2 BARGAINING POWER OF BUYERS 64
5.1.3 THREAT OF NEW ENTRANTS 64
5.1.4 THREAT OF SUBSTITUTES 64
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 65
5.2 MACROECONOMIC INDICATORS 65
5.2.1 INTRODUCTION 65
5.2.2 GDP TRENDS AND FORECAST 65
5.3 SUPPLY CHAIN ANALYSIS 68
5.4 VALUE CHAIN ANALYSIS 69
5.5 ECOSYSTEM ANALYSIS 71
5.5.1 MULTIPLEX ASSAY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 72
5.6 PRICING ANALYSIS 72
5.6.1 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY KEY PLAYER, 2024–2026 72
5.6.2 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY REGION, 2024–2026 73
5.7 TRADE ANALYSIS 75
5.7.1 IMPORT SCENARIO (HS CODE 3822) 75
5.7.2 EXPORT SCENARIO (HS CODE 3822) 76
5.8 KEY CONFERENCES AND EVENTS, 2026–2027 76
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 77
5.10 INVESTMENT AND FUNDING SCENARIO 78

5.11 IMPACT OF 2025 US TARIFF ON MULTIPLEX ASSAY MARKET 78
5.11.1 INTRODUCTION 78
5.11.2 KEY TARIFF RATES 79
5.11.3 PRICE IMPACT ANALYSIS 79
5.11.4 IMPACT ON REGION 80
5.11.4.1 North America 80
5.11.4.2 Europe 80
5.11.4.3 Asia Pacific 81
5.11.5 IMPACT ON END-USE INDUSTRIES 81
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 82
6.1 KEY EMERGING TECHNOLOGIES 82
6.1.1 MULTIPLEX REAL-TIME PCR 82
6.1.2 FLOW CYTOMETRY 82
6.2 COMPLEMENTARY TECHNOLOGIES 83
6.2.1 BIOINFORMATICS 83
6.2.2 MICROFLUIDICS 83
6.3 ADJACENT TECHNOLOGIES 84
6.3.1 NEXT-GENERATION SEQUENCING 84
6.3.2 DIGITAL PCR 84
6.4 TECHNOLOGY/PRODUCT ROADMAP 85
6.5 PATENT ANALYSIS 86
6.5.1 LIST OF KEY PATENTS 87
6.6 FUTURE APPLICATIONS 88
6.7 IMPACT OF AI/GENERATIVE AI ON MULTIPLEX ASSAY MARKET 89
6.7.1 INTRODUCTION 89
6.7.2 TOP USE CASES AND MARKET POTENTIAL 90
6.7.3 KEY COMPANIES IMPLEMENTING AI 91
6.7.4 FUTURE OF AI 91
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 92
7.1 REGIONAL REGULATIONS AND COMPLIANCE 92
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
7.2 SUSTAINABILITY INITIATIVES 94
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN MULTIPLEX ASSAYS 94
7.2.1.1 Eco-friendly initiatives 94
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 95

8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR 96
8.1 DECISION-MAKING PROCESS 96
8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 96
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 96
8.2.2 BUYING CRITERIA 97
8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 98
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 99
8.5 MARKET PROFITABILITY 100
8.5.1 REVENUE POTENTIAL 100
8.5.2 COST DYNAMICS 100
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 101
9 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE 102
9.1 INTRODUCTION 103
9.2 CONSUMABLES 103
9.2.1 RECURRENT REQUIREMENTS AND PURCHASES OF CONSUMABLES TO DRIVE MARKET 103
9.3 INSTRUMENTS 106
9.3.1 LAUNCH OF TECHNOLOGICALLY ADVANCED INSTRUMENTS TO SUPPORT MARKET GROWTH 106
9.4 SOFTWARE & SERVICES 109
9.4.1 INCREASING NEED FOR EFFECTIVE DATA MANAGEMENT WITHIN LABORATORIES TO FUEL UPTAKE OF ADVANCED SOFTWARE 109
10 MULTIPLEX ASSAY MARKET, BY TYPE 113
10.1 INTRODUCTION 114
10.2 PROTEIN MULTIPLEX ASSAYS 114
10.2.1 BEAD-BASED PROTEIN ASSAYS 117
10.2.1.1 Best suited to study protein-protein interactions 117
10.2.2 PLANAR PROTEIN ASSAYS 120
10.2.2.1 Pivotal role in drug discovery to support uptake 120
10.2.3 OTHER PROTEIN ASSAYS 123
10.3 NUCLEIC ACID MULTIPLEX ASSAYS 125
10.3.1 BEAD-BASED NUCLEIC ACID ASSAYS 129
10.3.1.1 Increasing infectious diseases and genetic screening tests to drive market 129
10.3.2 PLANAR NUCLEIC ACID ASSAYS 132
10.3.2.1 Planar multiplex assays preferred in gene expression analysis, SNP genotyping, and transcriptome analysis 132
10.3.3 OTHER NUCLEIC ACID ASSAYS 135
10.4 CELL-BASED MULTIPLEX ASSAYS 137
10.4.1 BETTER VARIABILITY THAN BIOCHEMICAL-BASED ASSAYS TO DRIVE MARKET 137
11 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY 141
11.1 INTRODUCTION 142
11.2 FLOW CYTOMETRY 142
11.2.1 WIDE APPLICATIONS IN PROTEIN EXPRESSION, RNA, AND CELL HEALTH STATUS TO DRIVE SEGMENT 142
11.3 FLUORESCENCE DETECTION 145
11.3.1 INCREASING USE OF MICROARRAY SCANNERS AND FLUORESCENCE MICROSCOPES TO FUEL SEGMENT GROWTH 145
11.4 MULTIPLEX REAL-TIME PCR 148
11.4.1 HIGH SPECIFICITY AND SENSITIVITY OF MULTIPLEX REAL-TIME PCR TO DRIVE ADOPTION OF MULTIPLEX ASSAYS 148
11.5 LUMINESCENCE 151
11.5.1 RAPID AND EASY-TO-USE BENEFITS OF LUMINESCENCE TECHNOLOGY TO DRIVE MARKET 151
11.6 NEXT-GENERATION SEQUENCING (NGS) 154
11.6.1 RISING ADOPTION OF CUSTOMIZED AND APPLICATION-SPECIFIC NGS MULTIPLEX PANELS TO DRIVE MARKET 154
11.7 OTHER TECHNOLOGIES 157
12 MULTIPLEX ASSAY MARKET, BY APPLICATION 161
12.1 INTRODUCTION 162
12.2 RESEARCH & DEVELOPMENT 162
12.2.1 DRUG DISCOVERY & DEVELOPMENT 165
12.2.1.1 Multiplex assays massively employed in preclinical and clinical phases 165
12.2.2 BIOMARKER DISCOVERY & VALIDATION 168
12.2.2.1 Advancing biomarker discovery through global collaborative research networks 168
12.3 CLINICAL DIAGNOSTICS 171
12.3.1 INFECTIOUS DISEASES 174
12.3.1.1 Growing prevalence of infectious diseases to drive uptake of multiplex assays 174
12.3.2 CANCER 177
12.3.2.1 Rising burden of cancer to drive market 177
12.3.3 CARDIOVASCULAR DISEASES 181
12.3.3.1 High burden of cardiovascular diseases to support market growth 181
12.3.4 AUTOIMMUNE DISEASES 184
12.3.4.1 High incidence and prevalence of autoimmune diseases to drive demand for measures promoting early diagnosis 184
12.3.5 NERVOUS SYSTEM DISORDERS 187
12.3.5.1 Growing prevalence of nervous system disorders to fuel uptake of multiplex assays for early diagnosis and treatment 187
12.3.6 METABOLISM & ENDOCRINOLOGY DISORDERS 190
12.3.6.1 Multiplex assays used to measure endocrine and metabolic biomarkers help in timely diagnosis 190
12.3.7 OTHER DISEASES 193
13 MULTIPLEX ASSAY MARKET, BY END USER 196
13.1 INTRODUCTION 197
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 197
13.2.1 GROWING DEMAND FOR MULTIPLEX ASSAYS IN DRUG DISCOVERY & CLINICAL STUDIES TO DRIVE MARKET 197
13.3 HOSPITALS & DIAGNOSTIC LABORATORIES 200
13.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE MARKET 200
13.4 ACADEMIC & RESEARCH INSTITUTES 203
13.4.1 RISING GOVERNMENT FUNDING TO ACCELERATE MULTIPLEX ADOPTION IN ACADEMIC RESEARCH 203
13.5 CONTRACT RESEARCH ORGANIZATIONS 206
13.5.1 RISING OUTSOURCING OF DRUG DEVELOPMENT ACTIVITIES TO ACCELERATE MULTIPLEX ASSAY ADOPTION AMONG CROS 206
13.6 OTHER END USERS 209
14 MULTIPLEX ASSAY MARKET, BY REGION 213
14.1 INTRODUCTION 214
14.2 NORTH AMERICA 214
14.2.1 US 221
14.2.1.1 Increasing prevalence of infectious diseases and cancer to drive market 221
14.2.2 CANADA 225
14.2.2.1 Favorable government initiatives to fuel market 225
14.3 EUROPE 229
14.3.1 GERMANY 234
14.3.1.1 Strong healthcare infrastructure to drive market 234
14.3.2 UK 238
14.3.2.1 Expansion of diagnostic infrastructure to drive market 238
14.3.3 FRANCE 242
14.3.3.1 Strong R&D investments and growing disease burden to drive market 242
14.3.4 ITALY 246
14.3.4.1 Growing adoption of advanced diagnostics to drive market 246
14.3.5 SPAIN 250
14.3.5.1 Rising disease burden to drive market 250
14.3.6 REST OF EUROPE 254
14.4 ASIA PACIFIC 259
14.4.1 CHINA 264
14.4.1.1 Strong healthcare investments to drive market 264
14.4.2 JAPAN 268
14.4.2.1 Universal healthcare reimbursement policy to foster market growth 268

14.4.3 INDIA 272
14.4.3.1 Increased private and public investments to bolster growth 272
14.4.4 REST OF ASIA PACIFIC 276
14.5 LATIN AMERICA 281
14.5.1 BRAZIL 286
14.5.1.1 Rising disease burden and expanding research ecosystem to drive market 286
14.5.2 MEXICO 290
14.5.2.1 Rising chronic disease burden to drive market 290
14.5.3 REST OF LATIN AMERICA 294
14.6 MIDDLE EAST & AFRICA 298
14.6.1 GROWING HEALTHCARE INVESTMENTS AND RISING DEMAND FOR MULTIPLEX TESTING TO DRIVE MARKET 298
15 COMPETITIVE LANDSCAPE 303
15.1 INTRODUCTION 303
15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023–2026 303
15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MULTIPLEX ASSAY MARKET 304
15.3 REVENUE ANALYSIS, 2023–2025 305
15.4 MARKET SHARE ANALYSIS, 2025 306
15.4.1 MARKET SHARE ANALYSIS, 2025 306
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 308
15.5.1 STARS 308
15.5.2 EMERGING LEADERS 308
15.5.3 PERVASIVE PLAYERS 308
15.5.4 PARTICIPANTS 308
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 310
15.5.5.1 Company footprint 310
15.5.5.2 Region footprint 310
15.5.5.3 Product & service footprint 311
15.5.5.4 Application footprint 311
15.5.5.5 End user footprint 312
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 313
15.6.1 PROGRESSIVE COMPANIES 313
15.6.2 RESPONSIVE COMPANIES 313
15.6.3 DYNAMIC COMPANIES 313
15.6.4 STARTING BLOCKS 313
15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 315
15.6.5.1 Detailed list of key startups/SMEs 315
15.6.5.2 Competitive benchmarking of key startups/SMEs (1/2) 316
15.6.5.3 Competitive benchmarking of key startups/SMEs (2/2) 316

15.7 COMPANY VALUATION AND FINANCIAL METRICS 317
15.7.1 FINANCIAL METRICS 317
15.7.2 COMPANY VALUATION 317
15.8 BRAND/PRODUCT COMPARISON 318
15.9 COMPETITIVE SCENARIO 319
15.9.1 PRODUCT LAUNCHES & APPROVALS 319
15.9.2 DEALS 320
15.9.3 EXPANSIONS 321
16 COMPANY PROFILES 322
16.1 KEY PLAYERS 322
16.1.1 ILLUMINA, INC. 322
16.1.1.1 Business overview 322
16.1.1.2 Products offered 323
16.1.1.3 Recent developments 325
16.1.1.3.1 Product launches & approvals 325
16.1.1.3.2 Deals 325
16.1.1.4 MnM view 326
16.1.1.4.1 Right to win 326
16.1.1.4.2 Strategic choices 326
16.1.1.4.3 Weaknesses & competitive threats 326
16.1.2 BIO-RAD LABORATORIES, INC. 327
16.1.2.1 Business overview 327
16.1.2.2 Products offered 328
16.1.2.3 Recent developments 329
16.1.2.3.1 Product launches & approvals 329
16.1.2.3.2 Deals 330
16.1.2.4 MnM view 330
16.1.2.4.1 Right to win 330
16.1.2.4.2 Strategic choices 330
16.1.2.4.3 Weaknesses & competitive threats 330
16.1.3 THERMO FISHER SCIENTIFIC INC. 331
16.1.3.1 Business overview 331
16.1.3.2 Products offered 332
16.1.3.3 Recent developments 334
16.1.3.3.1 Product launches & approvals 334
16.1.3.3.2 Deals 334
16.1.3.4 MnM view 335
16.1.3.4.1 Right to win 335
16.1.3.4.2 Strategic choices 335
16.1.3.4.3 Weaknesses & competitive threats 335

16.1.4 DIASORIN S.P.A. 336
16.1.4.1 Business overview 336
16.1.4.2 Products offered 337
16.1.4.3 Recent developments 338
16.1.4.3.1 Product launches & approvals 338
16.1.4.3.2 Deals 339
16.1.4.4 MnM view 340
16.1.4.4.1 Right to win 340
16.1.4.4.2 Strategic choices 340
16.1.4.4.3 Weaknesses & competitive threats 340
16.1.5 BIOMÉRIEUX 341
16.1.5.1 Business overview 341
16.1.5.2 Products offered 342
16.1.5.3 Recent developments 343
16.1.5.3.1 Product launches & approvals 343
16.1.5.3.2 Deals 344
16.1.5.4 MnM view 344
16.1.5.4.1 Right to win 344
16.1.5.4.2 Strategic choices 345
16.1.5.4.3 Weaknesses & competitive threats 345
16.1.6 BECTON, DICKINSON AND COMPANY 346
16.1.6.1 Business overview 346
16.1.6.2 Products offered 347
16.1.6.3 Recent developments 348
16.1.6.3.1 Product launches & approvals 348
16.1.6.3.2 Deals 349
16.1.7 QIAGEN N.V. 350
16.1.7.1 Business overview 350
16.1.7.2 Products offered 351
16.1.7.3 Recent developments 352
16.1.7.3.1 Product launches & approvals 352
16.1.7.3.2 Deals 353
16.1.8 MERCK KGAA 354
16.1.8.1 Business overview 354
16.1.8.2 Products offered 355
16.1.8.3 Recent developments 356
16.1.8.3.1 Deals 356
16.1.8.3.2 Expansions 356

16.1.9 AGILENT TECHNOLOGIES, INC. 358
16.1.9.1 Business overview 358
16.1.9.2 Products offered 359
16.1.9.3 Recent developments 360
16.1.9.3.1 Product launches & approvals 360
16.1.9.3.2 Deals 360
16.1.10 DANAHER CORPORATION 361
16.1.10.1 Business overview 361
16.1.10.2 Products offered 362
16.1.10.3 Recent developments 363
16.1.10.3.1 Product launches & approvals 363
16.1.10.3.2 Deals 364
16.1.11 REVVITY, INC. 365
16.1.11.1 Business overview 365
16.1.11.2 Products offered 366
16.1.11.3 Recent developments 367
16.1.11.3.1 Product launches & approvals 367
16.1.11.3.2 Deals 368
16.1.12 F. HOFFMANN-LA ROCHE LTD 369
16.1.12.1 Business overview 369
16.1.12.2 Products offered 370
16.1.12.3 Recent developments 371
16.1.12.3.1 Product launches & approvals 371
16.1.12.3.2 Deals 372
16.1.13 QUANTERIX CORPORATION 373
16.1.13.1 Business overview 373
16.1.13.2 Products offered 374
16.1.13.3 Recent developments 375
16.1.13.3.1 Product launches & approvals 375
16.1.13.3.2 Deals 376
16.2 OTHER PLAYERS 377
16.2.1 BIO-TECHNE CORPORATION 377
16.2.2 SEEGENE INC. 378
16.2.3 MESO SCALE DIAGNOSTICS LLC 379
16.2.4 RANDOX LABORATORIES LTD. 380
16.2.5 STANDARD BIOTOOLS INC. 381
16.2.6 HOLOGIC, INC. 382
16.2.7 ABBOTT LABORATORIES 383
16.2.8 SIEMENS HEALTHINEERS AG 384
16.2.9 ENZO BIOCHEM INC. 385
16.2.10 SHIMADZU CORPORATION 386
16.2.11 PROMEGA CORPORATION 387
16.2.12 BOSTER BIOLOGICAL TECHNOLOGY 388
17 RESEARCH METHODOLOGY 389
17.1 RESEARCH DATA 389
17.1.1 SECONDARY RESEARCH 390
17.1.1.1 Key data from secondary sources 391
17.1.2 PRIMARY DATA 392
17.1.2.1 Primary sources 392
17.1.2.2 Key data from primary sources 393
17.1.2.3 Key industry insights 394
17.2 MARKET SIZE ESTIMATION 395
17.2.1 BOTTOM-UP APPROACH 396
17.2.1.1 Approach 1: Company revenue estimation approach 396
17.2.1.2 Approach 2: Presentations of companies and primary interviews 397
17.2.1.3 Growth forecast 397
17.2.2 TOP-DOWN APPROACH 398
17.3 MARKET BREAKDOWN AND DATA TRIANGULATION 399
17.4 MARKET SHARE ANALYSIS 399
17.5 RESEARCH ASSUMPTIONS 400
17.5.1 PARAMETRIC ASSUMPTIONS 400
17.5.2 GROWTH RATE ASSUMPTIONS 400
17.6 RESEARCH LIMITATIONS 401
17.7 RISK ASSESSMENT 401
18 APPENDIX 402
18.1 DISCUSSION GUIDE 402
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 406
18.3 CUSTOMIZATION OPTIONS 408
18.4 RELATED REPORTS 408
18.5 AUTHOR DETAILS 409

LIST OF TABLES

TABLE 1 ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV (ALL AGES): 2010, 2023,
AND 2024 (MILLION PEOPLE) 51
TABLE 2 ESTIMATED NUMBER OF NEW CANCER CASES IN BOTH SEXES: AGE 0-85+,
2022–2045 51
TABLE 3 TOTAL TB INCIDENCE, 2024 51
TABLE 4 IMPACT OF PORTER’S FIVE FORCES ON MULTIPLEX ASSAY MARKET 64
TABLE 5 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 65
TABLE 6 NORTH AMERICA: MACROECONOMIC INDICATORS 66
TABLE 7 EUROPE: MACROECONOMIC INDICATORS 67
TABLE 8 ASIA PACIFIC: MACROECONOMIC INDICATORS 67
TABLE 9 LATIN AMERICA: MACROECONOMIC INDICATORS 67
TABLE 10 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 67
TABLE 11 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 73
TABLE 12 AVERAGE SELLING PRICE OF MULTIPLEX ASSAY PRODUCTS, BY REGION,
2024–2026 (USD) 74
TABLE 13 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2025 (USD MILLION) 75
TABLE 14 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2025 (USD MILLION) 76
TABLE 15 MULTIPLEX ASSAY MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 76
TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES 79
TABLE 17 KEY PATENTS IN MULTIPLEX ASSAY MARKET, 2022–2026 87
TABLE 18 KEY COMPANIES IMPLEMENTING AI IN MULTIPLEX ASSAY MARKET 91
TABLE 19 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 20 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 21 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 22 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 23 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS,
BY PRODUCT & SERVICE (%) 97
TABLE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 97
TABLE 26 ADOPTION BARRIERS AND INTERNAL CHALLENGES 98
TABLE 27 MULTIPLEX ASSAY MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 99
TABLE 28 MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 103
TABLE 29 MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY REGION,
2024–2031 (USD MILLION) 104
TABLE 30 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 104
TABLE 31 EUROPE: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY,
2024–2031 (USD MILLION) 105
TABLE 32 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 105
TABLE 33 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 106
TABLE 34 GLOBAL: NUMBER OF MULTIPLEX ANALYZERS INSTALLED, 2024–2031 (UNITS) 107
TABLE 35 MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY REGION,
2024–2031 (USD MILLION) 107
TABLE 36 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 107
TABLE 37 EUROPE: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY,
2024–2031 (USD MILLION) 108
TABLE 38 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 108
TABLE 39 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 109
TABLE 40 MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY REGION,
2024–2031 (USD MILLION) 110
TABLE 41 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 110
TABLE 42 EUROPE: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 111
TABLE 43 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 111
TABLE 44 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR SOFTWARE & SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 112
TABLE 45 MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 114
TABLE 46 MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY TYPE,
2024–2031 (USD MILLION) 115
TABLE 47 MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY REGION,
2024–2031 (USD MILLION) 115
TABLE 48 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 49 EUROPE: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 50 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 51 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PROTEIN MULTIPLEX ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 117
TABLE 52 MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY REGION, 2024–2031 (USD MILLION) 118
TABLE 53 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 54 EUROPE: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 55 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 56 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 120
TABLE 57 MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY REGION,
2024–2031 (USD MILLION) 121
TABLE 58 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 59 EUROPE: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 60 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 61 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR PROTEIN ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 62 MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY REGION,
2024–2031 (USD MILLION) 123
TABLE 63 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 64 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 65 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 66 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER PROTEIN ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 67 SOME FDA-AUTHORIZED MULTIPLEX ASSAYS AND INSTRUMENTS FOR SIMULTANEOUS DETECTION OF INFLUENZA 126
TABLE 68 MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 127
TABLE 69 MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION) 127
TABLE 70 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 71 EUROPE: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 72 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 73 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NUCLEIC ACID MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 74 MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION) 130
TABLE 75 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 76 EUROPE: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 77 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 78 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BEAD-BASED NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 79 MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION) 133
TABLE 80 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 81 EUROPE: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 82 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 83 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PLANAR NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 84 MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY REGION, 2024–2031 (USD MILLION) 135
TABLE 85 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 86 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 87 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 88 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER NUCLEIC ACID ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 89 MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY REGION, 2024–2031 (USD MILLION) 138
TABLE 90 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 91 EUROPE: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 92 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 93 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CELL-BASED MULTIPLEX ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 94 MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 142
TABLE 95 MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY REGION,
2024–2031 (USD MILLION) 143
TABLE 96 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY,
BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 97 EUROPE: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 98 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 99 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 100 MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY REGION,
2024–2031 (USD MILLION) 146
TABLE 101 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 102 EUROPE: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION,
BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 103 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION,
BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 104 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR FLUORESCENCE DETECTION,
BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 105 MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR, BY REGION,
2024–2031 (USD MILLION) 149
TABLE 106 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR,
BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 107 EUROPE: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR,
BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 108 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR,
BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 109 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR MULTIPLEX REAL-TIME PCR,
BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 110 MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY REGION,
2024–2031 (USD MILLION) 152
TABLE 111 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 112 EUROPE: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY,
2024–2031 (USD MILLION) 153
TABLE 113 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 114 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR LUMINESCENCE, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 115 MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS),
BY REGION, 2024–2031 (USD MILLION) 155
TABLE 116 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 117 EUROPE: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 118 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 119 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 120 MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION,
2024–2031 (USD MILLION) 158
TABLE 121 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 122 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 123 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 124 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 125 MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 162
TABLE 126 MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE,
2024–2031 (USD MILLION) 162
TABLE 127 MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION,
2024–2031 (USD MILLION) 163
TABLE 128 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 129 EUROPE: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 130 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 131 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR RESEARCH & DEVELOPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 132 MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 166
TABLE 133 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 134 EUROPE: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 135 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 136 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 137 MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION,
BY REGION, 2024–2031 (USD MILLION) 169
TABLE 138 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 139 EUROPE: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 140 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 141 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 142 MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE,
2024–2031 (USD MILLION) 171
TABLE 143 MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY REGION,
2024–2031 (USD MILLION) 172
TABLE 144 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 145 EUROPE: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 146 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 147 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CLINICAL DIAGNOSTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 148 MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION,
2024–2031 (USD MILLION) 175
TABLE 149 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 150 EUROPE: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 151 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 152 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 153 ESTIMATED NUMBER OF CANCER CASES IN BOTH SEXES (AGE 0-85+), BY REGION, 2022 VS. 2030 178
TABLE 154 MULTIPLEX ASSAY MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION) 179
TABLE 155 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 179
TABLE 156 EUROPE: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 180
TABLE 157 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 180
TABLE 158 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 181
TABLE 159 MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION,
2024–2031 (USD MILLION) 182
TABLE 160 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 161 EUROPE: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 162 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 163 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 164 MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY REGION,
2024–2031 (USD MILLION) 185
TABLE 165 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 166 EUROPE: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 167 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 168 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 169 MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY REGION, 2024–2031 (USD MILLION) 188
TABLE 170 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 171 EUROPE: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 172 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 173 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 174 MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY REGION, 2024–2031 (USD MILLION) 191
TABLE 175 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 176 EUROPE: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 177 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 178 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR METABOLISM & ENDOCRINOLOGY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 179 MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY REGION,
2024–2031 (USD MILLION) 193
TABLE 180 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 181 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY,
2024–2031 (USD MILLION) 194
TABLE 182 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 183 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 184 MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 197
TABLE 185 MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 198
TABLE 186 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 187 EUROPE: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 188 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 189 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 190 MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES,
BY REGION, 2024–2031 (USD MILLION) 201
TABLE 191 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 192 EUROPE: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 193 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 194 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 195 MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 204
TABLE 196 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 197 EUROPE: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 198 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 199 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 200 MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,
BY REGION, 2024–2031 (USD MILLION) 207
TABLE 201 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 202 EUROPE: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 203 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 204 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 205 MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY REGION,
2024–2031 (USD MILLION) 210
TABLE 206 NORTH AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 207 EUROPE: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 208 ASIA PACIFIC: MULTIPLEX ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 209 LATIN AMERICA: MULTIPLEX ASSAY MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 210 MULTIPLEX ASSAY MARKET, BY REGION, 2024–2031 (USD MILLION) 214
TABLE 211 NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE 215
TABLE 212 NORTH AMERICA: MACROECONOMIC INDICATORS 217
TABLE 213 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 217
TABLE 214 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 217
TABLE 215 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 218
TABLE 216 NORTH AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 218
TABLE 217 NORTH AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 218
TABLE 218 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 219
TABLE 219 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 219
TABLE 220 NORTH AMERICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 219
TABLE 221 NORTH AMERICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 220
TABLE 222 NORTH AMERICA: MULTIPLEX ASSAY MARKET, BY END USER,
2024–2031 (USD MILLION) 220
TABLE 223 US: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 221
TABLE 224 US: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 222
TABLE 225 US: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 222
TABLE 226 US: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 222
TABLE 227 US: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 223
TABLE 228 US: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 223
TABLE 229 US: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 223
TABLE 230 US: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 224
TABLE 231 US: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 224
TABLE 232 CANADA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 225
TABLE 233 CANADA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 226
TABLE 234 CANADA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 226
TABLE 235 CANADA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 226
TABLE 236 CANADA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 227
TABLE 237 CANADA: MULTIPLEX ASSAY MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 227
TABLE 238 CANADA: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 227
TABLE 239 CANADA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 228
TABLE 240 CANADA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 228
TABLE 241 EUROPE: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE 230
TABLE 242 MACROECONOMIC INDICATORS FOR EUROPE 230
TABLE 243 EUROPE: MULTIPLEX ASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 244 EUROPE: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 231
TABLE 245 EUROPE: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 231
TABLE 246 EUROPE: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 232
TABLE 247 EUROPE: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 232
TABLE 248 EUROPE: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 232
TABLE 249 EUROPE: MULTIPLEX ASSAY MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 233
TABLE 250 EUROPE: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 233
TABLE 251 EUROPE: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 233
TABLE 252 EUROPE: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 234
TABLE 253 GERMANY: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 235
TABLE 254 GERMANY: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 235
TABLE 255 GERMANY: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 235
TABLE 256 GERMANY: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 236
TABLE 257 GERMANY: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 236
TABLE 258 GERMANY: MULTIPLEX ASSAY MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 236
TABLE 259 GERMANY: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 237
TABLE 260 GERMANY: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 237
TABLE 261 GERMANY: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 238
TABLE 262 UK: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 239
TABLE 263 UK: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 264 UK: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 265 UK: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 240
TABLE 266 UK: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 240
TABLE 267 UK: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 240
TABLE 268 UK: RESEARCH & DEVELOPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 241
TABLE 269 UK: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 241
TABLE 270 UK: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 242
TABLE 271 FRANCE: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 243
TABLE 272 FRANCE: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 243
TABLE 273 FRANCE: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 244
TABLE 274 FRANCE: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 244
TABLE 275 FRANCE: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 244
TABLE 276 FRANCE: MULTIPLEX ASSAY MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 245
TABLE 277 FRANCE: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 245
TABLE 278 FRANCE: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 245
TABLE 279 FRANCE: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 246
TABLE 280 ITALY: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 247
TABLE 281 ITALY: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 282 ITALY: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 283 ITALY: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 248
TABLE 284 ITALY: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 248
TABLE 285 ITALY: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 249
TABLE 286 ITALY: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 249
TABLE 287 ITALY: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 249
TABLE 288 ITALY: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 250
TABLE 289 SPAIN: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 251
TABLE 290 SPAIN: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 291 SPAIN: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 292 SPAIN: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 252
TABLE 293 SPAIN: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 252
TABLE 294 SPAIN: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 252
TABLE 295 SPAIN: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 253
TABLE 296 SPAIN: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 253
TABLE 297 SPAIN: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 254
TABLE 298 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 255
TABLE 299 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 255
TABLE 300 REST OF EUROPE: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 256
TABLE 301 REST OF EUROPE: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 256
TABLE 302 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 257
TABLE 303 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 257
TABLE 304 REST OF EUROPE: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 257
TABLE 305 REST OF EUROPE: CLINICAL DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 258
TABLE 306 REST OF EUROPE: MULTIPLEX ASSAY MARKET, BY END USER,
2024–2031 (USD MILLION) 258
TABLE 307 MACROECONOMIC INDICATORS FOR ASIA PACIFIC 260
TABLE 308 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 261
TABLE 309 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 261
TABLE 310 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 261
TABLE 311 ASIA PACIFIC: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 262
TABLE 312 ASIA PACIFIC: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 262
TABLE 313 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 262
TABLE 314 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 263
TABLE 315 ASIA PACIFIC: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 263
TABLE 316 ASIA PACIFIC: CLINICAL DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 263
TABLE 317 ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY END USER,
2024–2031 (USD MILLION) 264
TABLE 318 CHINA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 265
TABLE 319 CHINA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 265
TABLE 320 CHINA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 266
TABLE 321 CHINA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 266
TABLE 322 CHINA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 266
TABLE 323 CHINA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 267
TABLE 324 CHINA: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 267
TABLE 325 CHINA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 267
TABLE 326 CHINA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 268
TABLE 327 JAPAN: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 269
TABLE 328 JAPAN: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 269
TABLE 329 JAPAN: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 270
TABLE 330 JAPAN: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 270
TABLE 331 JAPAN: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 270
TABLE 332 JAPAN: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 271
TABLE 333 JAPAN: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 271
TABLE 334 JAPAN: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 271
TABLE 335 JAPAN: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 272
TABLE 336 INDIA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 273
TABLE 337 INDIA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 273
TABLE 338 INDIA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 339 INDIA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 274
TABLE 340 INDIA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 274
TABLE 341 INDIA: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 275
TABLE 342 INDIA: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 275
TABLE 343 INDIA: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 344 INDIA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 276
TABLE 345 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 277
TABLE 346 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 277
TABLE 347 REST OF ASIA PACIFIC: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 278
TABLE 348 REST OF ASIA PACIFIC: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 278
TABLE 349 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 279
TABLE 350 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 279
TABLE 351 REST OF ASIA PACIFIC: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 279
TABLE 352 REST OF ASIA PACIFIC: CLINICAL DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 280
TABLE 353 REST OF ASIA PACIFIC: MULTIPLEX ASSAY MARKET, BY END USER,
2024–2031 (USD MILLION) 280
TABLE 354 MACROECONOMIC INDICATORS FOR LATIN AMERICA 281
TABLE 355 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 282
TABLE 356 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 282
TABLE 357 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 282
TABLE 358 LATIN AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 283
TABLE 359 LATIN AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 283
TABLE 360 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 284
TABLE 361 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 284
TABLE 362 LATIN AMERICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 284
TABLE 363 LATIN AMERICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 285
TABLE 364 LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY END USER,
2024–2031 (USD MILLION) 285
TABLE 365 BRAZIL: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 287
TABLE 366 BRAZIL: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 287
TABLE 367 BRAZIL: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 287
TABLE 368 BRAZIL: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 288
TABLE 369 BRAZIL: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 288
TABLE 370 BRAZIL: MULTIPLEX ASSAY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 288
TABLE 371 BRAZIL: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 289
TABLE 372 BRAZIL: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 289
TABLE 373 BRAZIL: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 290
TABLE 374 MEXICO: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE,
2024–2031 (USD MILLION) 291
TABLE 375 MEXICO: MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 291
TABLE 376 MEXICO: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 292
TABLE 377 MEXICO: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 292
TABLE 378 MEXICO: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 292
TABLE 379 MEXICO: MULTIPLEX ASSAY MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 293
TABLE 380 MEXICO: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 293
TABLE 381 MEXICO: CLINICAL DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 293
TABLE 382 MEXICO: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031 (USD MILLION) 294
TABLE 383 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 295
TABLE 384 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 295
TABLE 385 REST OF LATIN AMERICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 295
TABLE 386 REST OF LATIN AMERICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 296
TABLE 387 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 296
TABLE 388 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 297
TABLE 389 REST OF LATIN AMERICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 297
TABLE 390 REST OF LATIN AMERICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 297
TABLE 391 REST OF LATIN AMERICA: MULTIPLEX ASSAY MARKET, BY END USER,
2024–2031 (USD MILLION) 298
TABLE 392 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 299
TABLE 393 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 300
TABLE 394 MIDDLE EAST & AFRICA: PROTEIN MULTIPLEX ASSAY MARKET, BY TYPE,
2024–2031 (USD MILLION) 300
TABLE 395 MIDDLE EAST & AFRICA: NUCLEIC ACID MULTIPLEX ASSAY MARKET, BY TYPE, 2024–2031 (USD MILLION) 300
TABLE 396 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 301
TABLE 397 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 301
TABLE 398 MIDDLE EAST & AFRICA: RESEARCH & DEVELOPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 301
TABLE 399 MIDDLE EAST & AFRICA: CLINICAL DIAGNOSTICS MARKET, BY TYPE,
2024–2031 (USD MILLION) 302
TABLE 400 MIDDLE EAST & AFRICA: MULTIPLEX ASSAY MARKET, BY END USER,
2024–2031 (USD MILLION) 302
TABLE 401 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN MULTIPLEX ASSAY MARKET, JANUARY 2023−APRIL 2026 304
TABLE 402 MULTIPLEX ASSAY MARKET: DEGREE OF COMPETITION 306
TABLE 403 MULTIPLEX ASSAY MARKET: REGION FOOTPRINT 310
TABLE 404 MULTIPLEX ASSAY MARKET: PRODUCT & SERVICE FOOTPRINT 311
TABLE 405 MULTIPLEX ASSAY MARKET: APPLICATION FOOTPRINT 311
TABLE 406 MULTIPLEX ASSAY MARKET: END USER FOOTPRINT 312
TABLE 407 MULTIPLEX ASSAY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 315
TABLE 408 MULTIPLEX ASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES (1/2) 316
TABLE 409 MULTIPLEX ASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES (2/2) 316
TABLE 410 MULTIPLEX ASSAY MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–APRIL 2026 319
TABLE 411 MULTIPLEX ASSAY MARKET: DEALS, JANUARY 2023–APRIL 2026 320
TABLE 412 MERCK KGAA: EXPANSIONS, JANUARY 2023– APRIL 2026 321
TABLE 413 ILLUMINA, INC.: COMPANY OVERVIEW 322
TABLE 414 ILLUMINA, INC: PRODUCTS OFFERED 323
TABLE 415 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 325
TABLE 416 ILLUMINA, INC.: DEALS, JANUARY 2023–APRIL 2026 325
TABLE 417 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 327
TABLE 418 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 328
TABLE 419 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–APRIL 2026 329
TABLE 420 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023–APRIL 2026 330
TABLE 421 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 331
TABLE 422 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 332
TABLE 423 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–APRIL 2026 334
TABLE 424 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–APRIL 2026 334
TABLE 425 DIASORIN S.P.A.: COMPANY OVERVIEW 336
TABLE 426 DIASORIN S.P.A.: PRODUCTS OFFERED 337
TABLE 427 DIASORIN S.P.A.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–APRIL 2026 338
TABLE 428 DIASORIN S.P.A.: DEALS, JANUARY 2023–APRIL 2026 339
TABLE 429 BIOMÉRIEUX: COMPANY OVERVIEW 341
TABLE 430 BIOMÉRIEUX: PRODUCTS OFFERED 342
TABLE 431 BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 343
TABLE 432 BIOMÉRIEUX: DEALS, JANUARY 2023–APRIL 2026 344
TABLE 433 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 346
TABLE 434 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 347
TABLE 435 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 348
TABLE 436 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2023–APRIL 2026 349
TABLE 437 QIAGEN N.V.: COMPANY OVERVIEW 350
TABLE 438 QIAGEN N.V.: PRODUCTS OFFERED 351
TABLE 439 QIAGEN N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 352
TABLE 440 QIAGEN N.V.: DEALS, JANUARY 2023–APRIL 2026 353
TABLE 441 MERCK KGAA: COMPANY OVERVIEW 354
TABLE 442 MERCK KGAA: PRODUCTS OFFERED 355
TABLE 443 MERCK KGAA: DEALS, JANUARY 2023–APRIL 2026 356
TABLE 444 MERCK KGAA: DEALS, JANUARY 2023– APRIL 2026 356
TABLE 445 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 358
TABLE 446 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 359
TABLE 447 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–APRIL 2026 360
TABLE 448 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023–APRIL 2026 360
TABLE 449 DANAHER CORPORATION: COMPANY OVERVIEW 361
TABLE 450 DANAHER CORPORATION: PRODUCTS OFFERED 362
TABLE 451 DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–APRIL 2026 363
TABLE 452 DANAHER CORPORATION: DEALS, JANUARY 2023–APRIL 2026 364
TABLE 453 REVVITY, INC.: COMPANY OVERVIEW 365
TABLE 454 REVVITY, INC.: PRODUCTS OFFERED 366
TABLE 455 REVVITY, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 367
TABLE 456 REVVITY, INC.: DEALS, JANUARY 2023–APRIL 2026 368
TABLE 457 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 369
TABLE 458 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 370
TABLE 459 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–APRIL 2026 371
TABLE 460 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2023–APRIL 2026 372
TABLE 461 QUANTERIX CORPORATION: COMPANY OVERVIEW 373
TABLE 462 QUANTERIX CORPORATION: PRODUCTS OFFERED 374
TABLE 463 QUANTERIX CORPORATION: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–APRIL 2026 375
TABLE 464 QUANTERIX CORPORATION: DEALS, JANUARY 2023–APRIL 2026 376
TABLE 465 BIO-TECHNE CORPORATION: COMPANY OVERVIEW 377
TABLE 466 SEEGENE INC.: COMPANY OVERVIEW 378
TABLE 467 MESO SCALE DIAGNOSTICS LLC: COMPANY OVERVIEW 379
TABLE 468 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW 380
TABLE 469 STANDARD BIOTOOLS INC.: COMPANY OVERVIEW 381
TABLE 470 HOLOGIC, INC.: COMPANY OVERVIEW 382
TABLE 471 ABBOTT LABORATORIES: COMPANY OVERVIEW 383
TABLE 472 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 384
TABLE 473 ENZO BIOCHEM INC.: COMPANY OVERVIEW 385
TABLE 474 SHIMADZU CORPORATION: COMPANY OVERVIEW 386
TABLE 475 PROMEGA CORPORATION: COMPANY OVERVIEW 387
TABLE 476 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW 388
TABLE 477 MULTIPLEX ASSAY MARKET: RISK ASSESSMENT 401

LIST OF FIGURES

FIGURE 1 MULTIPLEX ASSAY MARKET SEGMENTATION 36
FIGURE 2 MARKET HIGHLIGHTS AND KEY INSIGHTS 40
FIGURE 3 MULTIPLEX ASSAY MARKET, 2024–2031 41
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MULTIPLEX ASSAY MARKET, 2023–2025 41
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF MULTIPLEX ASSAY MARKET 42
FIGURE 6 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN MULTIPLEX ASSAY MARKET, 2026-2031 43
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 44
FIGURE 8 RISING CASES OF CARDIOVASCULAR DISEASES TO DRIVE MARKET 45
FIGURE 9 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 46
FIGURE 10 PROTEIN MULTIPLEX ASSAYS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 46
FIGURE 11 MULTIPLEX REAL-TIME PCR SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 47
FIGURE 12 RESEARCH & DEVELOPMENT SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 47
FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 48
FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 48
FIGURE 15 MULTIPLEX ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49
FIGURE 16 MULTIPLEX ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 63
FIGURE 17 MULTIPLEX ASSAY MARKET: SUPPLY CHAIN ANALYSIS 69
FIGURE 18 MULTIPLEX ASSAY MARKET: VALUE CHAIN ANALYSIS 70
FIGURE 19 MULTIPLEX ASSAY MARKET: ECOSYSTEM ANALYSIS 71
FIGURE 20 MULTIPLEX ASSAY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 77
FIGURE 21 NUMBER OF DEALS AND FUNDING ACTIVITIES IN MULTIPLEX ASSAY MARKET 78
FIGURE 22 APPLIED AND GRANTED PATENTS, 2016–2025 86
FIGURE 23 MARKET POTENTIAL OF AI IN MULTIPLEX ASSAY MARKET 90
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 96
FIGURE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 97
FIGURE 26 NORTH AMERICA: MULTIPLEX ASSAY MARKET SNAPSHOT 216
FIGURE 27 ASIA PACIFIC: MULTIPLEX ASSAY MARKET SNAPSHOT 260
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN MULTIPLEX ASSAY MARKET,
2023–2025 (USD MILLION) 305
FIGURE 29 MULTIPLEX ASSAY MARKET SHARE ANALYSIS, 2025 306
FIGURE 30 MULTIPLEX ASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 309
FIGURE 31 MULTIPLEX ASSAY MARKET: COMPANY FOOTPRINT 310
FIGURE 32 MULTIPLEX ASSAY MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2025 314
FIGURE 33 EV/EBITDA OF KEY VENDORS 317
FIGURE 34 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK
BETA OF KEY VENDORS 317
FIGURE 35 MULTIPLEX ASSAY MARKET: BRAND/PRODUCT COMPARISON
FOR MULTIPLEX INSTRUMENTS 318
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 323
FIGURE 37 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 328
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 332
FIGURE 39 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025) 337
FIGURE 40 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 342
FIGURE 41 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025) 347
FIGURE 42 QIAGEN N.V.: COMPANY SNAPSHOT (2025) 351
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2025) 355
FIGURE 44 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 359
FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 362
FIGURE 46 REVVITY, INC.: COMPANY SNAPSHOT (2025) 366
FIGURE 47 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 370
FIGURE 48 QUANTERIX CORPORATION: COMPANY SNAPSHOT (2025) 374
FIGURE 49 RESEARCH DESIGN 389
FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 395
FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 395
FIGURE 52 MULTIPLEX ASSAY MARKET: REVENUE SHARE ANALYSIS 396
FIGURE 53 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 397
FIGURE 54 TOP-DOWN APPROACH 398
FIGURE 55 DATA TRIANGULATION METHODOLOGY 399

---

---